By clinical endpoint, significant reduction in circulating apelin concentration was found in ACS (WMD: -1.690 ng/mL, P = 0.005) or CAD (WMD: -1.099 ng/mL, P = 0.011) patients when compared with controls, and only marginally significant reduction was found in AMI patients. This evidence concerns the gene APLN and coronary artery disorder.